By staff writers

November 8, 2019 -- San Francisco-based Lexent Bio has signed a nonexclusive deal to adapt its lead investigational Confera Dx next-generation sequencing (NGS) cancer test for use with Illumina's NextSeq 550Dx sequencer.

Confera Dx is designed to monitor treatment response and the level of minimal residual disease (MRD) in cancer patients. The company plans to launch the product as a laboratory-developed test (LDT) with testing done at its own CLIA lab, and Lexent will also pursue clearance by the U.S. Food and Drug Administration (FDA) to enable use in the local labs of hospitals and health systems.

In its tie-up with Illumina, Lexent will manage regulatory approvals and Illumina will sell associated sequencing consumables for the NextSeq system.

AMP roundup: Vendors showcase same-day NGS, faster prep, DNA/RNA combos
BALTIMORE - Bruce Carlson, publisher of Kalorama Information, is on the ground at the Baltimore Convention Center for this week's Association for Molecular...
CMS plans broader coverage for NGS in breast, ovarian cancer
The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed broad national coverage for next-generation sequencing (NGS) in Medicare patients...
Qiagen tie-up with Illumina is a sign of the IVD times
Qiagen and Illumina have signed a 15-year strategic partnership on IVD tests that will take advantage of their respective strengths in companion diagnostics...
Adaptive partners with Illumina for IVD test kits
Adaptive Biotechnologies is partnering with Illumina to bring to market IVD test kits for Adaptive's current and future portfolio of immunodiagnostics...
Illumina files patent dispute with BGI
Illumina announced on May 15 that it filed a patent infringement suit in Denmark against BGI Group's European subsidiary, in a move it said is aimed at...

Copyright © 2019

Last Updated np 11/8/2019 2:30:59 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.